2022 / 04

DOI: 10.47183/mes.2022.049

ORIGINAL RESEARCH

Neutralizing antibody creation technologies: case of SARS-CoV-2

Baklaushev VP1,2,3, Samoilova EM1,2, Kuznetsova SM1, Ermolaeva EV2, Yusubalieva GM1,2, Kalsin VA1,2, Lipatova AV2, Troitsky AV1
About authors

1 Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies, Federal Medical Biological Agency of Russia, Moscow, Russia

2 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia

3 Research Institute of Pulmonology, Federal Medical Biological Agency of Russia, Moscow, Russia

Correspondence should be addressed: Vladimir P. Baklaushev
Orexovyj bul'var, 28, g. Moscow, 115682, Russia; ur.abmf-cknf@pv.vehsualkab

About paper

Funding: the study was supported financially by the Ministry of Science and Higher Education of the Russian Federation (contract #075-15-2021-1086, contract #RF----193021X0015, 15.IP.21.0015).

Received: 2022-11-29 Accepted: 2022-12-20 Published online: 2022-12-30
|